Allergy Clinical Trial
Official title:
Validation Study of the ALYATEC Allergen Exposure Chamber by Determining the Concentration of House Dust Mite Allergen Inducing Early and/or Late Bronchial Response in Asthmatic Subjects Allergic to Mite
Verified date | December 2020 |
Source | Alyatec |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized, double blind, cross-over study designed to determine the concentration of airborne house dust mite allergen inducing bronchial response in asthmatic subjects allergic to mite, during allergen exposures in the Alyatec environmental exposure chamber (EEC). The study was also designed to validate the specificity of the asthmatic reaction induced by exposure to airborne house dust mite allergen in Alyatec EEC.
Status | Completed |
Enrollment | 27 |
Est. completion date | February 15, 2017 |
Est. primary completion date | January 23, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - Subjects having signed the informed consent - Subjects affiliated to a social security scheme - Positive metacholine test - FEV1 value > 70% of theoretical FEV1 value - Asthma Control Test (ACT) = 20/25 in 4 weeks prior to EEC exposure Group A: - Mild allergic asthma to HDM (GINA 1 or 2) with associated rhinitis and/or conjunctivitis. - Positive skin prick-test to Dpt and Df (wheal diameter >5 mm compared to the negative control) - Specific immunoglobulin E (IgE) for Dpt and Df > 0.7 kU/L Group B: - Mild allergic asthma (GINA 1 or 2) not sensitized to HDM with associated rhinitis and/or conjunctivitis. - Negative skin prick-test and specific IgE for Dpt and Df. - Positive skin prick-test and specific IgE for another allergen. Exclusion Criteria: - Uncontrolled asthma - Asthma Control Test (ACT) < 20/25 in 4 weeks prior to EEC exposure - Use of oral corticosteroids in the 4 weeks preceding inclusion in the study - Use of biotherapy in the 4 months preceding inclusion in the study - Existence of a severe obstructive syndrome with FEV1 <70% of the theoretical value - Obstruction triggered by spirometric evaluations - Hospitalization for asthma or exacerbation in the last 4 weeks - History of Acute Severe Asthma requiring hospitalization in intensive care or intubation - Desensitization to dust mite allergens in the last 5 years - Sensitization to allergens in the indoor environment (cat allergens or molds) with obvious exposure to these allergens - Active tobacco: plus 10 cigarettes / day and tobacco history of +10 PA - Uncontrolled systemic arterial hypertension - Recent myocardial infarction (<3 months) - Recent stroke (<3 months) - Known arterial aneurysm - Epilepsy under treatment - Progressive tumor pathology - Chronic renal pathology - Hypersensitivity to one of the excipients used - Subjects who participated in another clinical study in the three months prior to inclusion |
Country | Name | City | State |
---|---|---|---|
France | Alyatec | Strasbourg | Grand Est |
Lead Sponsor | Collaborator |
---|---|
Alyatec |
France,
Khayath N, Doyen V, Gherasim A, Radu C, Choual I, Beck N, Jacob A, Schoettel F, Vecellio L, Domis N, de Blay F. Validation of Strasbourg environmental exposure chamber (EEC) ALYATEC(®) in mite allergic subjects with asthma. J Asthma. 2020 Feb;57(2):140-14 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determine the concentration of HDM allergen (in ng/m3 of Der p1) necessary to induce a bronchial response in at least 60% of asthmatic subjects allergic to HDM | The bronchial response is evaluated by measuring FEV1 value during EEC exposure.
Early asthmatic response (EAR) occurs when a 20% drop in FEV1 is detected during the exposure compared to the pre-exposure FEV1. Late bronchial response (LAR) occurs when a 15% drop in FEV1 or 20% drop in peak flow is detected 1 to 6h after the EAR. |
10 hours: 4 hours of exposure in the EEC then 6 hours post-exposure. | |
Secondary | Evaluate the safety of allergenic exposure in EEC | Safety is assessed with clinical evaluations performed during the 4h of exposure in the EEC | 28 hours: 4 hours of exposure in EEC then 24 hours post-exposure | |
Secondary | Evaluate the metrology of the EEC | The metrology is assessed with the measure of allergen concentration and particules diameter thanks to sensors in the chamber. | 4 hours of exposure in EEC | |
Secondary | Evaluate the specificity of the bronchial response | The specificity of the bronchial response is assessed with the HDM exposure in the EEC of asthmatic subjects non allergic to HDM. | 4 hours of exposure in EEC | |
Secondary | Evaluate the effect of the exposure on rhinitis symptoms | The effect of the exposure on the rhinitis response is assessed with Total Nasal Symptom Score (TNSS).
The TNSS was obtained from the sum of all four individual symptom scores, with a total possible score ranging from 0 (no symptoms) to 12 (maximum symptom intensity). |
28 hours: 4 hours of exposure in EEC then 24 hours post-exposure | |
Secondary | Evaluate the effect of the exposure on conjunctivitis symptoms | The effect of the exposure on the conjunctivitis response is assessed with Total Ocular Symptom Score (TOSS).
The TOSS was obtained from the sum of all four individual symptom scores, with a total possible score ranging from 0 (no symptoms) to 12 (maximum symptom intensity). |
28 hours: 4 hours of exposure in EEC then 24 hours post-exposure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02032056 -
Effect of Probiotics in Reducing Infections and Allergies in Young Children During the Complementary Feeding Period
|
N/A | |
Completed |
NCT01842711 -
Cumulative Irritation Patch Test
|
N/A | |
Completed |
NCT01633840 -
New Validated Recipes for Double-blind Placebo-controlled Low Dose Food Challenges
|
N/A | |
Completed |
NCT00997971 -
Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein
|
Phase 3 | |
Completed |
NCT00554983 -
Efficacy and Safety From a Recombinant Folding Variant of Bet v 1
|
Phase 3 | |
Completed |
NCT00331929 -
Respiratory Health Study of Children in Kiryat Tivon
|
N/A | |
Completed |
NCT00220753 -
Air Cleaners for Children and Adolescents With Asthma and Dog Allergy
|
N/A | |
Completed |
NCT00232518 -
Randomised Controlled Clinical Trials of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis
|
N/A | |
Completed |
NCT04126096 -
Negative Predictive Value and NIC of Beta-Lactam Antibiotics.
|
N/A | |
Completed |
NCT04046731 -
Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation
|
N/A | |
Completed |
NCT04004351 -
Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or Asthma
|
||
Not yet recruiting |
NCT05997784 -
Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing
|
||
Completed |
NCT04418999 -
Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus
|
Early Phase 1 | |
Completed |
NCT04186949 -
Early Origins of Allergy and Asthma
|
||
Completed |
NCT02127801 -
Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants
|
Phase 1 | |
Enrolling by invitation |
NCT05011071 -
The Alberta BLOOM Premature Child Study
|
||
Not yet recruiting |
NCT06330974 -
Allergy, Asthma, and Atopic Eczema in Finland
|
||
Completed |
NCT02306473 -
The Leaky Lung Test
|
Early Phase 1 | |
Completed |
NCT02596321 -
A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma
|
Phase 3 | |
Terminated |
NCT02601690 -
Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America
|